GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Senzime AB (OSTO:SEZI) » Definitions » Debt-to-EBITDA

Senzime AB (OSTO:SEZI) Debt-to-EBITDA : -0.12 (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Senzime AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Senzime AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr2.65 Mil. Senzime AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr8.58 Mil. Senzime AB's annualized EBITDA for the quarter that ended in Mar. 2024 was kr-92.52 Mil. Senzime AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.12.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Senzime AB's Debt-to-EBITDA or its related term are showing as below:

OSTO:SEZI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.11   Med: -0.04   Max: -0.01
Current: -0.1

During the past 13 years, the highest Debt-to-EBITDA Ratio of Senzime AB was -0.01. The lowest was -0.11. And the median was -0.04.

OSTO:SEZI's Debt-to-EBITDA is ranked worse than
100% of 427 companies
in the Medical Devices & Instruments industry
Industry Median: 1.26 vs OSTO:SEZI: -0.10

Senzime AB Debt-to-EBITDA Historical Data

The historical data trend for Senzime AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Senzime AB Debt-to-EBITDA Chart

Senzime AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.07 -0.02 -0.11 -0.10

Senzime AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 -0.10 -0.12 -0.08 -0.12

Competitive Comparison of Senzime AB's Debt-to-EBITDA

For the Medical Devices subindustry, Senzime AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Senzime AB's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Senzime AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Senzime AB's Debt-to-EBITDA falls into.



Senzime AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Senzime AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.89 + 8.578) / -115.902
=-0.10

Senzime AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.648 + 8.575) / -92.52
=-0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Senzime AB  (OSTO:SEZI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Senzime AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Senzime AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Senzime AB (OSTO:SEZI) Business Description

Traded in Other Exchanges
Address
Ulls vag 41, Uppsala, SWE, 756 51
Senzime AB, a medical technology company, develops, manufactures, and markets patient monitoring systems for monitoring patients. Its solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease healthcare costs. Its product includes TetraGraph and TetraSens, ExSpiron, TetraSens Pediatric, and TetraConnect. Its geographical segments include Sweden, the United States, Europe/Oceania, and Asia.

Senzime AB (OSTO:SEZI) Headlines

No Headlines